G20 podium
NEW DELHI: Union Health Minister Mansukh Mandaviya on July 11 directed the Drugs Controller General of India (DCGI) to take stringent actions against those pharmaceutical manufacturing companies that make spurious drugs.
“It is important for MSME pharma companies to be alert to quality of drugs and expeditiously move towards Good Manufacturing Processes (GMP) through self-regulation,” the minister said as he met representatives from pharma companies in the MSME space.
“There shall be no compromise with the quality of drugs manufactured in India”, he emphasized, in apparent reference to companies engaged in making spurious drugs.
Strongly stressing on the need for self regulation in the MSME pharma sector, Mandaviya underscored its importance for India to maintain the status of ‘Pharmacy of the World ‘.
